Sulforaphane ( DrugBank: Sulforaphane )
2 diseases
告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
6 | パーキンソン病 | 1 |
205 | 脆弱X症候群関連疾患 | 1 |
6. パーキンソン病
臨床試験数 : 2,298 / 薬物数 : 2,202 - (DrugBank : 350) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 202
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT05084365 (ClinicalTrials.gov) | October 10, 2021 | 7/10/2021 | A 6-month Study to Evaluate Sulforaphane Effects in PD Patients | A 6-month Study to Evaluate Sulforaphane Effects in Treatment of Cognition Impairment of PD Patients | Parkinson Disease | Drug: Sulforaphane;Drug: Placebo | Central South University | NULL | Not yet recruiting | 40 Years | 75 Years | All | 100 | Phase 2 | NULL |
205. 脆弱X症候群関連疾患
臨床試験数 : 5 / 薬物数 : 13 - (DrugBank : 7) / 標的遺伝子数 : 25 - 標的パスウェイ数 : 29
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT05233579 (ClinicalTrials.gov) | June 25, 2021 | 20/10/2021 | Open-Label Trial of Sulforaphane in Premutation Carriers With FXTAS | Open-Label Trial of Sulforaphane in Premutation Carriers With FXTAS to Find Biomarkers | Fragile X Associated Tremor/Ataxia Syndrome (Fxtas) (Diagnosis) | Dietary Supplement: Sulforaphane | University of California, Davis | NULL | Recruiting | 50 Years | 85 Years | All | 15 | N/A | United States |